0       0

AMDA's 32nd Annual Symposium


B17 - This Year in Review for Long Term Care


Mar 6, 2009 1:30pm ‐ Mar 6, 2009 3:00pm

Standard: $24.00

Description

AMDCP Credit Designation:

This session has been approved for a total of 1.5 Clinical credit hours toward certification as a Certified Medical Director in Long Term Care (CMD).

The American Medical Directors Association designates this educational activity fora maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Presenter(s): Barbara J.Messinger-Rapport, MD, PhD, CMD; Julie Gammack, MD, CMD; John Morley, MB, BCh;Mary Pat Rapp, PhD, MSN, GNP

Disclosure(s):
John Morley, MB, BCH received grant/research Support from Ascend, Baxter, Numico, Nestle, and Danone and onthe Speaker's Bureau at Merck & Co, Novartis, Indevus, Orthobiotec, GTx, Amgen, Novartis Nutritional and Mattern. He is a consultantfor Novartis, Mattern Pharmaceuticals Amgen, Edunn Biotec, Indevus, Abbott, Glaxo Smith Kline, Cytokinetics,Ligand, and Baxter and has stocks in Mattern Pharm and Edunn Biotec.
MaryPat Rapp, PhD, MSN, GNP received an advisory panel fee from Ortho Biotech, L.P.Product(s) made by this company related to this topic: Erythropoietin.
Barbara J. Messinger-Rapport, MD, PhD, CMD received speaker honoraria from Forest Pharmaceuticals, Inc. and Novartis. Products made by these companies related to this topic: Reclase and Namenda.
Julie Gammack, MD, CMD has no relevant financial relationships to disclose.

Session Description:
This session presents 12-15 articles published in the pastyear which have the potential to impact the practice of medicine and theprocesses of care for frail elders in the long tern care continuum. Allarticles are chosen and critically appraised by a panel of experienced,multidisciplinary practitioners and educators. This presentation has been wellreceived each year and often inspires spirited discussion.

Learning Objectives:
  • Identify key articles that influence medical care, improve processesof care, reduce polypharmacy, improve non-pharmaceutical management ofbehavior, address ethical matters, and highlight public health issues inlong term care
  • Describe the population, intervention, control group, and outcome foreach study discussed
  • Apply the methods demonstrated here to journal articles in the futureto determine applicability to long term care practice

References:
Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidencebased medicine: what it is and what it isn't. BMJ. January 13, 19961996;312(7023):71-72.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content